COVID-19 Vaccine Acceptance in Azuay Province, Ecuador: A Cross-Sectional Online Survey.

COVID-9 Ecuador hesitancy vaccine acceptance

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
21 Jun 2021
Historique:
received: 24 04 2021
revised: 16 06 2021
accepted: 16 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

We investigated the COVID-19 vaccination acceptance level in Azuay province, Ecuador through an online survey from 12th to 26th February (before the start of the COVID-19 vaccination campaign in Ecuador). Overall, 1219 respondents participated in the survey. The mean age was 32 ± 13 years; 693 participants (57%) were female. In total, 1109 (91%) of the participants indicated they were willing to be vaccinated with a COVID-19 vaccine, if the vaccine is at least 95% effective; 835 (68.5%) if it is 90% effective and 493 (40.5%) if it is 70% effective; 676 (55.5%) participants indicated they feared side effects and 237 (19.4%) thought the vaccine was not effective. Older age, having had a postgraduate education, a history of a negative COVID-19 test, a high level of worry of contracting COVID-19, believing that COVID-19 infection can be prevented with a vaccine and understanding there is currently an effective vaccine against COVID-19 were associated with higher vaccination acceptance. A vaccination education campaign will be needed to increase the knowledge of Ecuadorians about the COVID-19 vaccine and to increase their trust in the vaccine. People with a lower education level and living in rural areas may need to be targeted during such a campaign.

Identifiants

pubmed: 34205483
pii: vaccines9060678
doi: 10.3390/vaccines9060678
pmc: PMC8235423
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : VLIRUOS (Flemish University development aid
ID : 36-7921

Références

Int J Environ Res Public Health. 2020 Aug 13;17(16):
pubmed: 32823775
Hum Vaccin Immunother. 2020 Nov 1;16(11):2604-2608
pubmed: 32703069
JAMA. 2020 Jun 23;323(24):2458-2459
pubmed: 32421155
Vaccine. 2020 Dec 3;38(51):8090-8098
pubmed: 33187765
J Health Psychol. 2010 Apr;15(3):446-55
pubmed: 20348365
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Vaccine. 2020 Jan 16;38(3):470-481
pubmed: 31767469
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Vaccines (Basel). 2021 May 17;9(5):
pubmed: 34067682
JAMA Netw Open. 2020 Oct 1;3(10):e2025594
pubmed: 33079199
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
Glob Public Health. 2022 Jun;17(6):1087-1098
pubmed: 33843459
Vaccine. 2021 Jan 8;39(2):247-254
pubmed: 33328140
Vaccine. 2016 Feb 17;34(8):1018-24
pubmed: 26672676
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
PLoS One. 2018 Dec 7;13(12):e0208601
pubmed: 30532274
Vaccines (Basel). 2020 Aug 27;8(3):
pubmed: 32867224
Vaccine. 2015 May 21;33(22):2530-5
pubmed: 25869886
BMJ. 2020 Jun 4;369:m2184
pubmed: 32499217
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):
pubmed: 33619178
Lancet. 2021 Mar 13;397(10278):1023-1034
pubmed: 33587887
Commun Med (Lond). 2021 Jul 16;1:16
pubmed: 35602197
Health Expect. 2020 Dec;23(6):1543-1578
pubmed: 33022806

Auteurs

Julio Jaramillo-Monge (J)

Faculty of Health Science, Universidad de Cuenca, Cuenca 010203, Ecuador.

Michael Obimpeh (M)

Family Medicine and Population Health, University of Antwerp, 2610 Antwerp, Belgium.

Bernardo Vega (B)

Faculty of Health Science, Universidad de Cuenca, Cuenca 010203, Ecuador.

David Acurio (D)

Faculty of Health Science, Universidad de Cuenca, Cuenca 010203, Ecuador.

Annelies Boven (A)

Family Medicine and Population Health, University of Antwerp, 2610 Antwerp, Belgium.

Veronique Verhoeven (V)

Family Medicine and Population Health, University of Antwerp, 2610 Antwerp, Belgium.

Robert Colebunders (R)

Family Medicine and Population Health, University of Antwerp, 2610 Antwerp, Belgium.

Classifications MeSH